Cutaneous T-cell lymphoma after dupilumab use: A real-world pharmacovigilance study of the FDA adverse event reporting system Research Letter

   

Authors:	Lavin, L.; Dusza, S.; Geller, S.
Title:	Cutaneous T-cell lymphoma after dupilumab use: A real-world pharmacovigilance study of the FDA adverse event reporting system
Keywords:	adult; controlled study; aged; middle aged; major clinical study; side effect; melanoma; food and drug administration; drug development; retrospective study; cutaneous t-cell lymphoma; cutaneous t cell lymphoma; lymphoma; etanercept; adverse drug reaction; biological product; pharmacology; adverse event; tumor necrosis factor inhibitor; infliximab; drug comparison; atopic dermatitis; cytokine receptor antagonist; adalimumab; human; male; female; article; pharmacovigilance; biologics; brodalumab; certolizumab pegol; ustekinumab; secukinumab; dupilumab; risankizumab; baricitinib; golimumab; guselkumab; ixekizumab; tildrakizumab
Journal Title:	Journal of Investigative Dermatology
Volume:	145
Issue:	1
ISSN:	0022-202X
Publisher:	Elsevier Science, Inc.
Date Published:	2025-01-01
Start Page:	211
End Page:	214.e1
Language:	English
DOI:	10.1016/j.jid.2024.06.1272
PUBMED:	38945437
PROVIDER:	scopus
PMCID:	PMC11625630
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85199055829&doi=10.1016%2fj.jid.2024.06.1272&partnerID=40&md5=2a938727cbd2ef47c846070c58d5feec
Notes:	The MSK Cancer Center Support Grant (P30 CA008748) is acknowledge in the PDF -- Corresponding authors is MSK authors: Shamir Geller -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/221387